PICO Portalanswers from OpenAlex
Pembrolizumab for Early Triple-Negative Breast Cancer
PaperCitations, authors & open-access status
Pembrolizumab for Early Triple-Negative Breast Cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does Pembrolizumab for Early Triple-Negative Breast Cancer have?
PICO Portalcitation count
Pembrolizumab for Early Triple-Negative Breast Cancer has 3,189 citations in the OpenAlex counts PICO Portal stores.
When was Pembrolizumab for Early Triple-Negative Breast Cancer published?
PICO Portalyear
Pembrolizumab for Early Triple-Negative Breast Cancer has 2020 year in the PICO Portal index.
What is the open-access status of Pembrolizumab for Early Triple-Negative Breast Cancer?
PICO Portaloa status
Pembrolizumab for Early Triple-Negative Breast Cancer has bronze oa status in the PICO Portal index.
What is the DOI of Pembrolizumab for Early Triple-Negative Breast Cancer?
PICO Portaldoi
The DOI for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.
What is the PMID of Pembrolizumab for Early Triple-Negative Breast Cancer?
PICO Portalpmid
The PMID for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.
What is the OpenAlex record for Pembrolizumab for Early Triple-Negative Breast Cancer?
PICO Portalopenalex
The OpenAlex for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.